Clinical Trials Browser

Phase NA × OTHER × osimertinib × Clear all

NCT06304441 2025-09-29

Intra-pemetrexed Plus Third-generation Small Molecule TKI Drugs (e.g. 'Osimertinib') Versus Third-generation Small Molecule TKI Drugs Alone for Leptomeningeal Metastasis From Epidermal Growth Factor Receptor Mutation-Positive Non-Small-cell Lung Cancer

Phase NA Recruiting

Meningeal Carcinomatosis

NCT03969823 2025-05-15

Whole Genomic Landscape of Advanced EGFR-mutant NSCLC

Phase NA Active not recruiting

Carcinoma, Non-Small-Cell Lung

NCT06709274 2024-11-29

MOTION-NSCLC

Phase NA Not yet recruiting

Carcinoma, Non-Small-Cell Lung

NCT05583409 2022-10-17

SBRT Combined With Osimertinib Compared With Osimertinib for Stage IV NSCLC

Phase NA Unknown

Carcinoma, Non-Small-Cell Lung

NCT04816838 2021-08-25

A Window of Opportunity Study for Investigating Drug Tolerant Persister (DTP) to Neoadjuvant Osimertinib in Resectable Non-small Cell Lung Cancer (NSCLC) Harbouring EGFR Mutations

Phase NA Unknown

Carcinoma, Non-Small-Cell Lung